Skip to content

Rigel Pharma initiates fostamatinib mid-stage study for COVID-19

September 17, 2020

Rigel Pharmaceuticals (NASDAQ:RIGL) rises 14% in premarket, in reaction to commencement of a Phase 2 trial of fostamatinib, its oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients.

The study is sponsored by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), in collaboration with Inova Health System.

Fostamatinib, marketed in the U.S. as TAVALISSE tablets, is approved in the U.S. and Europe as a treatment for adult chronic immune thrombocytopenia (characterized by abnormally low levels of platelets).

The study will enroll ~60 patients who require supplemental oxygen. Primary objective of the study is to evaluate the safety of fostamatinib compared to placebo in COVID-19, secondary objective include early efficacy and clinically relevant measures of disease progression.

Treatment will be administered orally twice daily for 14 days, with a follow-up period to day 60.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: